GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Equity-to-Asset

Immunic (STU:10VA) Equity-to-Asset : 0.80 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunic Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Immunic's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €76.89 Mil. Immunic's Total Assets for the quarter that ended in Mar. 2024 was €95.82 Mil.

The historical rank and industry rank for Immunic's Equity-to-Asset or its related term are showing as below:

STU:10VA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53   Med: 0.89   Max: 0.96
Current: 0.8

During the past 13 years, the highest Equity to Asset Ratio of Immunic was 0.96. The lowest was 0.53. And the median was 0.89.

STU:10VA's Equity-to-Asset is ranked better than
67.22% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:10VA: 0.80

Immunic Equity-to-Asset Historical Data

The historical data trend for Immunic's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Equity-to-Asset Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.95 0.91 0.89 0.53

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.78 0.72 0.53 0.80

Competitive Comparison of Immunic's Equity-to-Asset

For the Biotechnology subindustry, Immunic's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Immunic's Equity-to-Asset falls into.



Immunic Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Immunic's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=26.53/49.792
=

Immunic's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=76.89/95.823
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunic  (STU:10VA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Immunic Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Immunic's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (STU:10VA) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines